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The counterfeiting of pharmaceuticals, especially antimalarials, is a well-
recognized and growing public health problem. There have been an alarming number of 
reports of counterfeit antimalarials throughout the world and insufficient regulations and 
high demand for these very costly pharmaceuticals continues to fuel counterfeiting 
activity. Thus there is an urgent need for a rapid and sensitive authentication and 
screening tool for multiple antimalarials. While many methods have been developed 
using HPLC, MS, or LC-MS to screen individual antimalarials, no methods are available 
for the analysis of multiple antimalarial drugs within a single run. In this study, Liquid 
Chromatography-Tandem Mass Spectrometry (LC-MS/MS) with multiple reaction 
monitoring (MRM) was used as a selective and rapid way to screen ten common 
antimalarials. The compounds were first individually analyzed using electrospray 
ionization mass-spectrometry (ESI-MS). Following this, a corresponding MS/MS 
spectrum was obtained to enable selection of the optimal unimolecular decay 
fragmentation (“transition”) of each antimalarial. Finally, these single reaction 
monitoring (SRM) transitions were combined into a method that utilizes HPLC 
separation followed by multiple reaction monitoring (MRM) in an ion trap mass analyzer 
allowing for sequential screening of a mixture of these compounds within a single LC-
MS/MS run. This method has both pharmaceutical and medical applications with the 
capability of providing drug quality control measurements and the detection of many 




CHAPTER 1: INTRODUCTION 
 
Malaria is a disease caused by the protozoan parasite Plasmodium which is 
transmitted from person to person through bites from infected female Anopheles 
mosquitoes. The disease has grown into a significant global health crisis, and the crisis is 
still present today. Between 400 and 900 million cases of malaria are reported every year 
causing an average of 1 to 3 million deaths
1
. Since no vaccine is available for malaria, all 
treatments and preventatives come in the form of prescription drugs, called antimalarials. 
There are numerous antimalarials available, and often treatments will include a 
combination of two drugs. However, the high cost of and demand for antimalarials, 
which typically do not have a generic form, drive counterfeiting activity which severely 
impedes the prevention and treatment of the disease
2, 3
.  
Counterfeit antimalarials come in different forms. They can contain the wrong 
ingredient(s), not contain any active ingredient(s), or have insufficient levels of active 
ingredient(s). Counterfeit antimalarial drugs have been found in Africa, Asia and South 
America
4
, and very sophisticated fakes have been reported in Thailand, Vietnam, and 
Cambodia
5
. A survey from Cambodia showed 60% of antimalarials labeled as 
mefloquine contained ineffective and cheaper sulphadoxine-pyrimethamine
6, 7
 and a 
study in Southeast Asia revealed that 38% of 104 artesunate samples gathered were 
counterfeit
8
. The widespread nature of this problem has provided motivation for 
companies and academic research groups to develop new methods and technologies 




CHAPTER 2: LITERATURE REVIEW 
 
Several different physical and chemical tests can be used for the analysis of 
antimalarials. There are a variety of chemical tests available which range from testing for 
the presence of active ingredient in a tablet to quantifying the amount of antimalarial 
present in the bloodstream. The tests can also vary in complexity ranging from simple 
field tests to advanced analytical techniques
9
. Where high tech lab equipment may be 







, and a one-step fluorescence assay
12
 have been developed. While these are simple, 
inexpensive, and easy to perform, more in depth information on an antimalarial is 
typically needed or beneficial seeing that identification of a counterfeit antimalarial is 
only the first step in attacking the problem. Information on the type of counterfeiting and 
the drug’s origin can only be determined with more advanced techniques. 
Advanced screening techniques have the ability to provide crucial chemical 
information. These methods are often much more sophisticated than simple chemical 
techniques and are performed with highly developed laboratory equipment. Some 
advanced techniques that in recent years have been applied to antimalarials include liquid 
chromatography (LC) and high-performance liquid chromatography (HPLC)















, and liquid chromatography-mass 
spectrometry (LC-MS)





2.1 High Performance Liquid Chromatography (HPLC) 
HPLC is a widely used analytical technique that is used to separate, purify, or 
quantify components in a complex mixture based on component properties such as 
polarity, ionic charge, or size. Identification of a compound with HPLC requires the use 
of a detector coupled to the HPLC system. Therefore an HPLC detection system must 
first perform a separation assay that flows into the detector. 
HPLC methods have been applied to antimalarials, including the separation of 
impurities from a novel antimalarial drug 8-aminoquinolone
21
, and the separation of three 
antimalarial drugs, chloroquine, quinine, and mefloquine
4
. Additionally, Dr. Harparkash 
Kaur of the London School of Hygiene and Tropical Medicine recently developed an 
HPLC method to separate a number of antimalarials with UV-Vis detection
22
. While this 
method can separate a mixture of many antimalarials, UV-Vis detection is not as 
sensitive or selective as other detection options such as mass spectrometry. 
 
2.2 Mass Spectrometry (MS) 
Perhaps one of the most powerful and sensitive screening techniques available for 
antimalarial analysis is mass spectrometry (MS). A wide range of different MS 
techniques including accurate mass ESI MS, accurate mass tandem MS, and desorption 
electrospray-ionization (DESI) have been applied to different types of antimalarials
18, 19
. 
MS has a number of advantages over other analytical methods including high speed and 
sensitivity. However, like the antimalarial HPLC methods
4, 21
, all current antimalarial MS 
methods share the same limitation - they are designed to analyze a single drug or a small 




Liquid chromatography-mass spectrometry (LC-MS) is an analytical technique 
that couples the separation power of HPLC with the sensitive and selective identification 
power of mass spectrometry.  
Numerous methods using LC-MS have been developed for antimalarials. 





, pyrimethamine and sulfamethoxypyrazine
25
, and artesunate and 
dihydroartemesinin
26
 in plasma. Another method has also been developed for analysis of 
artemisinin from plant extracts
27
. But yet again, a major limitation of these methods is 




In summary, although the analysis of a mixture of different antimalarials using 
LC with UV detection has been demonstrated
22
 as has the development of varying LC-
MS methods for individual antimalarials
23-27
, no work has been published combining 
these two techniques. While each type of analytical method has unique advantages, one 
need that no recent HPLC, mass spectrometry, or LC-MS antimalarial method addresses 
is the simultaneous separation and identification of multiple antimalarial drugs within a 
single run. Where some of the referenced methods have been applied to a couple of 
different antimalarials, most have been developed solely for the analysis of a single drug 
4, 17-21, 23-27
.  
Therefore the goal of this project is to determine if the HPLC separation of 
multiple antimalarials can be successfully combined with tandem MS into one high-
 12 
throughput and sensitive screening tool. LC-MS was the technique of choice due to the 
ability to couple the separation power of HPLC with the highly specific and sensitive 
identification capabilities of MS.  
Due to the large number of different antimalarials on the market world-wide and 
the high incidences of counterfeiting, a method with these screening capabilities would 
be of great benefit in the pharmaceutical industry. Furthermore, many people in endemic 
malaria regions often self-medicate with combinations of antimalarial drugs and the 
ability to separate and detect these combination therapeutics could be applied to blood 
plasma samples as well. Ultimately, the ability to test a large number of drugs in a single, 
sensitive, and large scale assay creates the potential to save time, money, and ultimately 









CHAPTER 3: EXPERIMENTAL 
 
3.1 Standards, Solvents, and Sample Prep 
The antimalarials of interest for this project were chosen from those that Dr. Kaur 
successfully separated with HPLC
22
. The selected antimalarials were: amodiaquine, 
chloroquine, dapsone, dihydroquinine, mefloquine, primaquine, pyrimethamine, 
quinidine, quinine, sulfadoxine, and trimethoprim (See Appendix A for a description and 
structure of each). The solid standard for each antimalarial was purchased from Sigma-
Aldrich and was used without any further purification. 
 













Table I: Antimalarial standards purchased from Sigma-Aldrich. 
 
 
Stock solutions were prepared for each antimalarial in 50/50 (v/v) HPLC grade 
methanol (Sigma Aldrich, St. Louis, MO) and deionized water (18 MΩ cm
-1
, Barnstead 
International, Dubuque, IA). The standard solutions for ESI experiments were prepared in 
a 50/50 solution (v/v) of methanol (Sigma Aldrich, St. Louis, MO) and deionized water 
with 0.1 % acetic acid (Sigma Aldrich, St. Louis, MO). The antimalarial mixtures for LC-
 14 
MS/MS were prepared in deionized water. All sample solutions were prepared on a daily 
basis from stock solutions stored at -80º C. A solution that was 5 µM for each 
antimalarial was used during the optimization of the method while a set of standards (0.1, 
0.3, 0.5, and 1.0 µM) was used while calibrating the response of the system. The HPLC 
system utilized gradient elution of deionized water with 0.1% formic acid (Fisher 
Scientific, Waltham, MA) and acetonitrile (Sigma Aldrich, St. Louis, MO) with 0.1% 
formic acid as the solvents. All samples were filtered using a 0.45 µm PTFE membrane 
filter before analysis. 
Human plasma samples were prepared using 100 µL of plasma (Sigma Aldrich, 
St. Louis, MO) spiked with chloroquine, amodiaquine, or dihydroquinine. The mixture 
was then vortexed for 5 seconds and sonicated for 10 minutes. Next, the mixture was 
diluted to 300 µL with acetonitrile, vortexed for 10 seconds, and sonicated for 15 
minutes. Samples were then centrifuged at 13,000 g for 30 minutes. The resulting 
supernatant was pipetted into a clean centrifuge tube and the solvent was evaporated at 
45°C for approximately 3 hours. The residue was then reconstituted with 100 µL 
deionized water. Finally, after the sample was filtered with a 0.45 µm syringe filter it was 
ready for analysis.  
 
3.2 Experimental Procedures 
 
 The LC-MS/MS method development consisted of two main parts:  
(1)  Analyzing each antimalarial individually using continuous infusion 
electrospray ionization tandem mass spectrometry (ESI MS/MS) (See 
Appendix B for ESI description). 
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 (2)  Analyzing the mixture of antimalarials using LC-MS/MS.  
 
Each antimalarial standard was first run using ESI MS/MS to identify and select 
the unimolecular decay fragmentations (“transitions”) to be monitored for each drug. An 
optimized tune file method was then created for each. Following this step the LC-MS/MS 
experiments could be performed by setting up the method to screen for each 
fragmentation transition identified in (1) using multiple reaction monitoring (MRM) of a 
mixture of antimalarials (See Appendix B for MRM description). Further optimization of 
the method was the next experimental step. The final step was the creation of a 
calibration curve and subsequent analyses of spiked human plasma samples. 
 
3.3  LC-MS Instrumentation 
LC was performed on a LDC Analytical system equipped with a Constametric 
3200 solvent delivery system and a GM4000 gradient programmer, specifically 
assembled for this project. A 2.0 mm ID, 75 mm long Shim-Pack XR-ODS reverse-
phased column (Shimadzu, Columbia, MD) was used in all of the experiments. The LC 
was operated at a flow rate of 500 µL min
-1
 with an injection volume of 20 µL. The 
binary pump used deionized water with 0.1% formic acid as mobile phase A and a 95% 
acetonitrile solution with 0.1% formic acid as mobile phase B. The LC gradient started at 
20% B and ramped to 100% B in 10 minutes. The system was flushed with 100% mobile 
phase B following each run for approximately 10 minutes, and allowed to equilibrate to 
the original mobile phase composition before beginning another run. The HPLC 
 16 
instrument was coupled to a Thermo LCQ DECA XP+ quadrupolar ion trap mass 
spectrometer equipped with an electrospray ionization ion source. 
 
3.4 LC-MS/MS Software Set-Up 
 The LC-MS/MS method used Xcalibur software to set up and queue each run. 
The run time, individual transitions to monitor (up to 10), and method tune file were all 
entered under the instrument setup. Next the file name, file path, and instrument setup 
were entered into a sequence setup, which was then used to begin each run. The software 
could not interface with the HPLC pump controls, therefore all gradient adjustments were 







CHAPTER 4: RESULTS 
 
4.1 Identifying Antimalarial SRM Transitions 
Each antimalarial was run with ESI (in a 50:50 acetonitrile:water, 0.1% acetic 
acid solvent system) in positive and negative ion mode. Positive ion mode produced 
stronger signal and better fragmentation for the majority of the samples; therefore the 
method was developed using this mode. A mass spectrum was collected for each 
antimalarial once the precursor ion was identified. This peak was then optimized to 
obtain the maximum signal intensity (Figure I). After tuning, the precursor peak was then 
fragmented and a MS/MS spectrum was collected. The percent collision energy was 
optimized to produce a minimum but still visible precursor peak ion intensity and 
maximum fragment ion intensity (Figure II). Based upon the unique fragment ions 
identified for each antimalarial, a corresponding precursor to product ion transition was 
selected for each antimalarial and the single reaction monitoring (SRM) mass spectrum 




































Figure I: The positive mode full mass spectrum for the antimalarial chloroquine. The 
[M+H]
+
 peak appears at m/z 320.2, and the doubly-charged  [M+2H]
2+
































Figure II: The positive mode MS/MS (or MS
2
) spectrum for chloroquine showing the 
predominant fragment peak corresponding to [M-C4H11N+H]
+



















Figure III: The positive mode single reaction monitoring (SRM) spectrum, which 




4.2  Development of ESI Tune Files for Antimalarials 
After identifying the unique SRM transition for each antimalarial, a method tune 
file was created and saved for each drug. Some major variable conditions and the unique 




























Amodiaquine 34.18 300 20 36 1.0 356.1 283.2 
Chloroquine 13.98 300 5 36 1.0 320.1 247.2 
Dapsone 28.1 299.8 30 36 1.0 249.1 156.0 
Dihydroquinine 43.33 300 45 46 1.0 327.3 309.2 
Mefloquine 46.47 300.5 45 36 1.0 379.2 361.2 
Primaquine 25.03 299.8 0 30 1.0 260.1 243.2 
Pyrimethamine 2.85 300.2 25 53 1.0 249.3 233.1 
Quinidine 46.33 300 45 42 1.0 325.2 307.2 
Quinine 19.03 300.1 15 44 1.0 325.3 307.2 
Sulfadoxine 9.07 300.1 10 36 1.2 311.2 156.0 
Trimethoprim 2.78 300 -10 40 1.0 291.3 230.1 
 




4.3 HPLC Split Flow Experiment 
 In order to properly interface the HPLC to the mass spectrometer, a flow splitter 
was used to reduce the flow entering the mass spectrometer inlet and thus, the split ratio 
for the splitter valve had to be measured using a split flow experiment. This split flow 
ratios were determined for incremental turns of the splitter by massing the amount of 
deionized water (at 22ºC) collected from each line (sample and waste) in a two minute 
time period. The increments were measured by every half turn until the valve was 
completely open after 3.5 turns. In the region where the greatest change in flow ratio was 
observed, additional points were collected to provide a better indication of whether any 
reproducible intermediate flow ratios would be created. The experiment was performed at 
several different flow rates, but 0.5 mL/min was chosen as the final flow rate to be used 
for subsequent experiments, as it was the manufacturer’s recommended flow rate for the 
HPLC column used. No changes in the minimum or maximum sample flow rate through 
the splitter were observed while changing the overall pump flow rate. The experimental 
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data in Table III shows the calculated sample flow rate for a split flow experiment at 0.5 
mL/min.  
 
# Turns Waste Flow (mL/min) Sample Flow (mL/min) 
0.0 0.4743 0.0004 
0.5 0.4848 0.0003 
0.54 0.4089 0.1014 
0.58 0.4039 0.1016 
0.66 0.4037 0.1011 
0.75 0.4105 0.1055 
1.0 0.3880 0.0987 
1.25 0.4002 0.1051 
1.5 0.3947 0.1008 
2.0 0.3962 0.1007 
2.5 0.3961 0.1028 
3.0 0.3992 0.1044 
3.5 0.3982 0.1032 
 
Table III: A summary of the waste and sample line flow rates from a split flow ratio 






























Figure IV: A plot of the sample and waste flow rates determined from the split flow 
analysis at 0.5 mL/min. 
 
Figure IV shows the flow rates for the sample and waste line based on the 
numbers of turns the splitter is open at 0.5 mL/min. Since the max sample flow rate of the 
splitter is about 0.1 mL/min and this flow will work properly at the inlet of the ESI source 
on the mass spectrometer, all subsequent LC-MS/MS experiments were operated with the 
splitter fully opened.  
 
4.4 Optimization of LC-MS/MS Method 
 Once the individual ESI tune files and the split flow experiment were completed, 
the initial LC-MS/MS trials began. For preliminary experiments the duty cycle was split 
to scan for 5 antimalarials in each run. The antimalarials were sorted based on the 
compatibility of their respective ESI tune files; specifically they were sorted based on 
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whether they required a high or low tube lens offset. The gradient used for all preliminary 
experiments was 5 – 100% B ramped in 30 minutes. Once each antimalarial was detected, 
first the maximum injection time and AGC settings were adjusted to optimize the peaks. 
Next, all 10 antimalarials were combined into a single run, with the detection settings 




Sheath gas flow rate 14 
Capillary voltage (V) 19.03 
Capillary temp ( C) 300 
Tube lens (V, sp) 18.5 
Injection time (ms) 50 
# microscans 2 
Collision energy (%) 36 
 
Table IV: Tune file parameter settings for antimalarial mixture. 
 
 
Once each antimalarial was detected with these settings, the HPLC flow and solvent 
gradient were optimized. 
 
4.4.1 Flow Optimization 
For flow optimization, the antimalarial mixture (5 µM) was run 5 times with 
different flow rates ranging from 200 - 700 µL/min. Although a flow rate of 600 µL/min 
produced the best full width at half maximum (FWHM) as seen in Table V for 
amodiaquine, the HPLC pumps over-pressured and failed at this flow rate or higher when 
the gradient consisted of mostly water. For this reason and because the optimal flow rate 
for the column is 500 µL/min, this flow rate was chosen for all further experiments. 
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Flow Rate (µL/min) Retention Time (min) Area 
FWHM 
(min) 
200 9.63 185194233 1.60 
400 7.03 340325707 1.02 
500 5.27 257120535 0.67 
600 4.78 233182804 0.53 
700 6.41 263114507 0.61 
 
Table V: Chromatographic parameters for amodiaquine at five different flow rates using 
a 5 µM solution and 5-100% B gradient ramped in 30 minutes. (FWHM stands for full 
width at half maximum). 
 
 
4.4.2 Gradient Optimization 
 Once the optimal flow rate was determined, the gradient parameters were adjusted 
to further optimize the chromatography and shorten the run time. The initial gradient used 
for experimentation was 5-100% B ramped in 30 minutes. Since all of the antimalarials 
did not elute until after a 20% B concentration was reached, the first trial gradient was 
started at a higher, 15%, initial B concentration ramped for the same time, 30 minutes. 
This successfully eluted all antimalarials; however it did not improve the throughput of 
the method. Next, the same % B concentration was used, only this time the program was 
ramped in 15 minutes. Finally, an even faster method of 20-100% B in 10 minutes was 
also tested. As seen in Table VI, this final gradient setting produced the best FWHM and 
shortest run time, while still successfully eluting each antimalarial. Therefore this 







% B Ramp time (min) Retention Time (min) Area 
FWHM 
(min) 
15-100 30 5.41 49520327 1.38 
15-100 15 4.44 40126821 0.75 
20-100 10 2.5 51004074 0.70 
 
Table VI: Chromatographic parameters for amodiaquine with three different gradient 




4.4.3  Optimized Method 
The optimized method therefore consisted of the tune file settings from Table IV, 
a 500 µL/min flow rate, and 20-100% B gradient ramped in 10 minutes for a total run 
time of 10 minutes. Table VII summarizes the chromatographic parameters including 
retention time (RT), area, and FWHM for each antimalarial and Figure V displays the 
mass selected chromatograms for each as well.  
 
Antimalarial Transition Average RT Average Peak Area 
Average FWHM 
(min) 
Amodiaquine 356.1 - 283.2 2.87 ± 0.74 4.45E+07 ± 38 % 0.79 ± 0.13 
Chloroquine 320.1 - 247.2 2.77 ± 0.71 9.42E+07 ± 16.5 % 0.72 ± 0.14 
Dapsone 249.1 - 156.0 4.46 ± 0.19 2.90E+07 ± 3.6 % 1.30 ± 0.09 
Dihydroquinine 327.3 - 309.2 2.90 ± 0.58 4.36E+07 ± 33.8 % 1.15 ± 0.62 
Mefloquine 379.2 - 361.2 5.85 ± 0.21 1.50E+08 ± 120.1 % 1.26 ± 0.13 
Primaquine 260.1 - 243.2 4.12 ± 0.23 4.17E+07 ± 26 % 1.25 ± 0.27 
Pyrimethamine 249.3 - 233.1 3.99 ± 0.22 6.88E+04 ± 13.4 % 0.50 ± 0.13 
Quinine 325.3 - 307.2 2.95 ± 0.71 2.32E+07 ± 59.5 % 0.89 ± 0.22 
Sulfadoxine 311.2 - 156.0 4.76 ± 0.11 4.41E+07 ± 13.4 % 1.12 ± 0.21 
Trimethoprim 291.3 - 230.1 2.89 ± 0.67 1.20E+07 ± 6.5 % 0.68 ± 0.04 
  
Table VII: The averaged chromatographic parameters for each antimalarial with the 
optimized LC-MS/MS method. Three trials were performed using a 1 µM solution with a 
0.5 mL/min flow rate, 20-100% B gradient ramped in 10 minutes, and 10 minutes 



























































































Figure V: The chromatograms for each antimalarial using the optimized LC-MS/MS 
method with a 1 µM sample solution, 0.5 mL/min flow rate, and 20-100% B gradient 
ramped in 10 minutes. 
 
Each antimalarial was successfully detected with the optimized method. However, 
as evident in Figure V, the peak intensity for pyrimethamine was very low and was so 
consistently throughout all experiments. This was likely due to the very poor solubility of 
the drug, and the signal intensity could not be improved even with addition of acetonitrile 
or preparation of fresh stock solutions.  Additionally, a large variability of peak area was 
observed for a number of antimalarials as seen in Table VII.  Causes for this could 
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include inconsistencies with the pumps as the pressures during analysis oscillated 
irregularly, or a non-homogeneous sample mixture. 
Next, antimalarial mixtures of four different concentrations, 0.1, 0.3, 0.5, and 1.0 
µM, were run using the optimized method to produce a calibration curve for each 
antimalarial. The plot for each antimalarial, except for pyrimethamine which did not 
provide a strong signal at any concentration, and its corresponding linear regression and 
R
2
 value can be seen in Figure VI. Regression parameters are also summarized in Table 
VIII.   
Certain regression lines also did not intersect near the origin.  Reasons for this can 
be attributed to the fact that peaks for some antimalarials appeared with a 0.1 µM 
concentration, whereas all of the other drugs were undetected with this concentration.  
Since these solutions were prepared by serial dilution from a 1 µM solution, it is possible 
that some 1.0 µM solutions were prepared improperly, or carryover from previous runs 










































Figure VI: Calculated calibration curves for each antimalarial except pyrimethamine 
from 0.1, 0.3, 0.5, and 1.0 µM solutions. 
 
 
Compound Slope (m) Intercept (b) R
2
 
Amodiaquine 4.95E+07 -6.64E+06 0.980 
Chloroquine 8.24E+07 -7.51E+06 0.994 
Dapsone 2.72E+07 1.99E+06 0.996 
Dihydroquinine 4.56E+07 -1.41E+06 0.964 
Mefloquine 4.38E+07 -2.10E+06 0.995 
Primaquine 4.07E+07 9.49E+05 0.998 
Quinine 2.56E+07 -3.80E+06 0.943 
Sulfadoxin 4.12E+07 3.02E+06 0.990 
Trimethoprim 1.16E+07 1.21E+05 0.968 
 
Table VIII: Regression data for antimalarial calibration curves. 





















































Amodiaquin Chloroquine Dapson Dihydroquinine Mefloquine
Primaquine Quinine Sulfadoxin Trimethoprim
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 The final step in method development was the preparation and analysis of control 
human plasma samples, each spiked with a different antimalarial. The identity of the 
antimalarial in each was unknown to the person performing the analysis. This tested the 
method’s ability to identify a single antimalarial from a sample, and also gave an estimate 
to the quantitative abilities based on the developed calibration curves. 
 Three different plasma samples were prepared, and the antimalarial in each was 
successfully identified as chloroquine, amodiaquine, and dihydroquinine. The 
chromatograms from the chloroquine sample are shown in Figure VII. Although 
chloroquine was correctly identified, another peak, mefloquine, was also visible in the 
chromatograms as seen in Figure VII. However, based on mefloquine’s peak intensity, 
retention time, and overall peak shape in comparison the chloroquine’s peak, it was 
deduced that mefloquine was not the spiked antimalarial, and the peak was rather a result 
of carryover or contamination from previous runs. The remaining antimalarial 


















































































Figure VII: Chromatograms for each antimalarial from an unknown spiked plasma 
sample. The unknown antimalarial for this sample was identified as chloroquine, 
although a weak and possibly contaminant mefloquine peak was also present. 
 
The concentration of each spiked antimalarial was also calculated using the 
resulting peak area and calibration curves. However, the calculated concentrations 17.0 
µM, 0.77 µM, and 0.19 µM were far from the actual prepared concentrations (5 µM, 0.4 
µM, and 0.6 µM, respectively). This may have been caused by either poor recovery of the 
antimalarial from the complex plasma matrix, or it may have been due to carryover 
between successive runs, indicating that the method will need further optimization before 
use to quantitate the amount of antimalarial present in a sample. 
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CHAPTER 5: CONCLUSIONS 
 
 This preliminary method development using LC-MS/MS confirms that multiple 
unrelated antimalarial drugs can be successfully separated and detected with high 
sensitivity using this technique. Each antimalarial was successfully separated and 
detected, and with the exception of pyrimethamine, each had excellent peak intensity and 
shape. However, a limitation of this method is that although the Xcalibur software will 
allow for a maximum of 20 different screening transitions to be performed per run, the 
corresponding reduction in the duty cycle, or scan time for each transition, may 
significantly limit the sensitivity. Therefore in order to screen for additional antimalarial 
drugs using this method, either the chromatographic separation of these compounds needs 
to be improved to allow for the scanning of a few transitions at different times during the 
run (which is possible using this software) or the analysis needs to be performed as two 
sequential runs scanning for different compounds. Both suggested solutions to this 
problem will reduce the throughput of the method but as the method is already relatively 
short, and currently the analysis of 120 antimalarials can be performed per hour (20 
antimalarials per run with a 10 minute run time), it is anticipated that the impact of these 
changes would be minimal.  
 Further work could also prepare the method for more accurate quantitative 
capabilities. Analysis of more samples using this approach, including the preparation and 
analysis of neat standards as well as standards prepared using complex biological 
matrices such as serum or plasma, would be beneficial for determining how accurate the 
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current quantitation actually is, and if the inaccuracies of the unknown plasma samples 
were due to the method, poor recovery of the drugs from the plasma, or carryover. 
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APPENDIX A: Antimalarial Structures 
1.  Amodiaquine 
Formula:   C20H22ClN3O   








Info: Also known as under the trade names Campoquin and Flavoquin. A 4-
aminoquinoline compound related to chloroquine. It is used as an antimalarial and 
anti-inflammatory, and has been shown to be more effective than chloroquine in 
treating chloroquine-resistant malaria infections. The drug is not marketed in the U.S. 
but is widely available in Africa. The drug form amodiaquine hydrochloride is 
readily absorbed from the gastrointestinal tract where it is converted in the liver to 
the active metabolite desethylamodiaquine. 
 
2. Chloroquine 
Formula:  C18H26ClN3  








Info: Chloroquine phosphate is a 4-aminoquinoline compound that is an antimalarial and 
immune suppressant drug. It is known to have resistance to the Plasmodium 
falciparum strains. It is also being investigated as an antiretroviral drug. Chloroquine 
can be used for preventing malaria from Plasmodium vivax, ovale and malariae. 
3. Dapsone 
Formula:   C12H12O2N2S 








Info: A drug used for malaria prevention that is commonly combined with other 
antimalarial preventatives. Like other sulpha drugs, dapsone inhibits dihydropteroate 





Formula:   C20H26N2O2  









Info: Dihydroquinine, also known simply as hydroquinine, is an organic compound and is 
a cinchona alkaloid closely related to quinine. 
  
5.  Mefloquine 
Formula:   C17H16F6N2O 










Info: An antimalarial agent found in the hydrochloride form.  
 
6.  Primaquine 
Formula:   C15H21N3O 








Info: Primaquine phosphate (C15H27N3O9P2) is an 8-amino-quinoline compound which 
eliminates tissue infection. It also prevents the development of the blood forms of 
malaria which are responsible for relapses. Primaquine phosphate is also active 
against gametocytes of Plasmodium falciparum 
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7. Pyrimethamine 
Formula:   C12H13ClN4  








Info: A component commonly found in the antimalarial drug Fansidar that is used in 
malaria preventatives and treatments. It is a folic acid antagonist that inhibits the 
activity of dihydrofolate reductase. It is active against the Plasmodium falciparum 
that are typically chloroquine resistant 
 
8.  Quinidine  
Formula:   C20H24N2O2  










Info: Quinidine is an antimalarial schizonticide and an antiarrhythmic agent. Quinidine 
sulfate is the sulfate salt of quinidine and it has an additional H2SO4 * 2H2O with its 
dimer structure. Intravenous quinidine is used for treatment of P. falciparum malaria. 
 
9. Quinine 
Formula:   C20H24N2O2  











Info: Quinine was the first effective treatment for falciparum malaria, appearing in 
therapeutics in the 17th century. It remained the antimalarial drug of choice until the 
1940s, when other drugs took over. Since then, many effective antimalarials have 
been introduced, although quinine is still used to treat the disease in certain critical 
situations. Quinine is available with a prescription in the United States. It is also used 





Formula:   C12H14N4O4S  











Info: A component commonly found in the antimalarial drug Fansidar. It is a folic acid 
antagonist that inhibits the activity of dihydropteroate synthase. It is active against 
the Plasmodium falciparum that are typically chloroquine resistant. 
 
11. Trimethoprim 
Formula:   C14H18N4O3   












Info: Trimethoprim was formerly marketed by GlaxoWellcome under trade names 
Proloprim, Monotrim and Triprim which have since been licensed to various generic 
pharmaceutical manufacturers. It is a bacteriostatic antibiotic commonly used to treat 
prophylaxis and prescribed for prevention of malaria. 
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APPENDIX B: Method Descriptions 
 
Multiple Reaction Monitoring (MRM): 
In single reaction monitoring (SRM) the mass spectrometer is set to scan for a 
specific ion produced by fragmentation of the corresponding precursor ion. This is 
accomplished by selecting the precursor mass of the compound for MS/MS 
fragmentation and then monitoring for a single fragment ion. Only ions formed by the 
cleavage of a particular precursor ion are detected and plotted. Thus, the SRM plot is 
highly sensitive and can be used to identify a given compound even in a complex mixture 
containing compounds with a similar precursor mass. Combining several SRM transitions 
into a single experiment, denoted as multiple reaction monitoring (MRM), provides the 
ability to simultaneously identify several components within a complex mixture. 
Therefore, MRM experiments can be used to provide more specific and sensitive 
analyses for each compound of interest as compared to conventional LC methods 
utilizing UV or diode array detection.  
 
 
Electrospray Ionization (ESI):  
Electrospray ionization (ESI) is a technique used in mass spectrometry to produce 
ions. In electrospray ionization, a liquid is pushed through a very small, charged and 
usually metal, capillary. This liquid contains the substance to be studied, the analyte, 
dissolved in a large amount of solvent, which is usually much more volatile than the 
analyte. The high voltage applied to the capillary induces charge separation in the liquid 
whereby charge of the opposite polarity to that of the applied voltage resides closest to 
the capillary surface while charge of the same polarity as the applied voltage exits the 
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capillary. Depending on the polarity of the applied voltage, either cationic or anionic 
species can be formed. As the liquid exits the capillary, repelling charges create an 
aerosol with the help of an uncharged carrier gas. The solvent then evaporates bringing 
analyte molecules closer together and thus causing more repulsion. This repeats until the 
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